[
  {
    "ts": "2026-02-17T07:00:00+00:00",
    "headline": "OSB GROUP PLC - Transaction in Own Shares",
    "summary": "OSB GROUP PLC ISIN: GB00BLDRH36017 February 2026 LEI number: 213800ZBKL9BHSL2K459 OSB GROUP PLC (the “Company”) Transaction in Own Shares The Company announces that on 16 February 2026 it had purchased a total of 78,427 of its ordinary shares of £0.01 each (the \"ordinary shares\") on the London Stock Exchange, CBOE BXE and CBOE CXE, through the Company's broker Citigroup Global Markets Limited as detailed below. The repurchased ordinary shares will be cancelled. London Stock ExchangeCBOE BXECBOE",
    "url": "https://finance.yahoo.com/news/osb-group-plc-transaction-own-070000318.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "1b31c3b3-42a8-3980-bb97-0098bb64f048",
      "content": {
        "id": "1b31c3b3-42a8-3980-bb97-0098bb64f048",
        "contentType": "STORY",
        "title": "OSB GROUP PLC - Transaction in Own Shares",
        "description": "",
        "summary": "OSB GROUP PLC ISIN: GB00BLDRH36017 February 2026 LEI number: 213800ZBKL9BHSL2K459 OSB GROUP PLC (the “Company”) Transaction in Own Shares The Company announces that on 16 February 2026 it had purchased a total of 78,427 of its ordinary shares of £0.01 each (the \"ordinary shares\") on the London Stock Exchange, CBOE BXE and CBOE CXE, through the Company's broker Citigroup Global Markets Limited as detailed below. The repurchased ordinary shares will be cancelled. London Stock ExchangeCBOE BXECBOE",
        "pubDate": "2026-02-17T07:00:00Z",
        "displayTime": "2026-02-17T07:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/248bac19f32fd60886158a1d6160336e",
          "originalWidth": 1159,
          "originalHeight": 1158,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6Tsy84jLTkGKZt7ZXARTQA--~B/aD0xMTU4O3c9MTE1OTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/248bac19f32fd60886158a1d6160336e.cf.webp",
              "width": 1159,
              "height": 1158,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/upN8zlYE9vk0OySt_m.pvg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/248bac19f32fd60886158a1d6160336e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/osb-group-plc-transaction-own-070000318.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/osb-group-plc-transaction-own-070000318.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "OSBGF"
            },
            {
              "symbol": "CBOE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-17T12:30:00+00:00",
    "headline": "Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder",
    "summary": "Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive symptoms as measured by MADRS score (mean difference: -7.35) versus placebo at two weeksAntidepressant treatment effects observed within one week and sustained for up to three months Findings reinforce the therapeutic potential of short-acting serotonergic agonists and inform Helus Pharma’s HLP004 development program, with Phase 2 topline data in general",
    "url": "https://finance.yahoo.com/news/nature-medicine-publishes-helus-pharma-123000387.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "0e9fbe4e-e4c3-35d8-9fd7-68b232e29ac1",
      "content": {
        "id": "0e9fbe4e-e4c3-35d8-9fd7-68b232e29ac1",
        "contentType": "STORY",
        "title": "Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder",
        "description": "",
        "summary": "Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive symptoms as measured by MADRS score (mean difference: -7.35) versus placebo at two weeksAntidepressant treatment effects observed within one week and sustained for up to three months Findings reinforce the therapeutic potential of short-acting serotonergic agonists and inform Helus Pharma’s HLP004 development program, with Phase 2 topline data in general",
        "pubDate": "2026-02-17T12:30:00Z",
        "displayTime": "2026-02-17T12:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/3450c05424aec5a369bb1a057d9bc5d2",
          "originalWidth": 5000,
          "originalHeight": 2625,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/K_.HcdnOklwtIB2nGyMt8g--~B/aD0yNjI1O3c9NTAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/3450c05424aec5a369bb1a057d9bc5d2.cf.webp",
              "width": 5000,
              "height": 2625,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jKD_XO40HSB8FywYVDEsaw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/3450c05424aec5a369bb1a057d9bc5d2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nature-medicine-publishes-helus-pharma-123000387.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nature-medicine-publishes-helus-pharma-123000387.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HELP"
            },
            {
              "symbol": "CBOE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]